.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,335,460

« Back to Dashboard

Summary for Patent: 6,335,460

Title: .alpha.-and .beta.-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors
Abstract:.alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
Inventor(s): Vazquez; Michael L. (Gurnee, IL), Mueller; Richard A. (Glencoe, IL), Talley; John J. (St. Louis, MO), Getman; Daniel (Chesterfield, MO), DeCrescenzo; Gary A. (St. Peters, MO), Freskos; John N. (Clayton, MO)
Assignee: G.D. Searle & Co. (Chicago, IL)
Application Number:09/510,189
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 3rd percentile
Forward Citations: 7th percentile
Patent PDF download available with subscription

No matches for this query

Premature patent expiration for: 6,335,460

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
6,335,460 January 01, 2014

International Patent Family for Patent: 6,335,460

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria172717<disabled in preview>
Austria174587<disabled in preview>
Austria218541<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc